Brainstorm Cell Therapeutics (BCLI) Misses Q1 EPS by 2c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q1 EPS of ($0.15), $0.02 worse than the analyst estimate of ($0.13).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank
• SWBI beats estimates by 71%, GEO nears 52-week high on policy tailwinds